Skip To Main Content
Samyukta Mullangi on Muck Rack

Samyukta Mullangi

Nashville
As seen in: HuffPost, Wiley Online Library, Harvard University, Harvard Business Review, Scientific American, JAMA (The Journal of the American Medical Association), JAMA Dermatology, JAMA Oncology, JAMA: Journal of the American Medical Association, Medscape and
Medical oncologist @TNOncology, Senior medical director @ThymeCares | I tweet about oncology, tech innovation, delivery system reform
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Samyukta

Contact Samyukta, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Insurers block biomarker testing. Why TN lawmakers must act | Opinion

|
By Samyukta Mullangi
| The Tennessean Verified
Without consistent insurance coverage, biomarker testing remains out of reach for many who need it most. Dr. Samyukta Mullangi Guest Columnist Feb. 18, 2026, 5:09 a.m. CT Recently, a patient of mine, a 52-year-old teacher and mother of three, faced a devastating diagnosis of advanced non-small cell lung cancer. I recommended biomarker testing—a cutting-edge diagnostic tool that could identify the genetic mutations driving her cancer.
Open in Who Shared Issue with article?

Insurers block biomarker testing. Why TN lawmakers must act | Opinion

|
By Samyukta Mullangi
| The Leaf-Chronicle Verified
Without consistent insurance coverage, biomarker testing remains out of reach for many who need it most. Dr. Samyukta Mullangi Guest Columnist Feb. 18, 2026, 5:09 a.m. CT Biomarker testing helps doctors create personalized cancer treatments with fewer side effects. Many health insurers deny coverage for this testing, calling it "experimental." Lack of insurance coverage creates significant access gaps, especially for underinsured populations.
Open in Who Shared Issue with article?

Oncologists Are Rethinking How They Adopt New Cancer Treatments, Report Shows

|
By Samyukta Mullangi
| Oncology News Central Verified
Oncologists Are Rethinking How They Adopt New Cancer Treatments, Report Shows Samyukta Mullangi, MD, MBA What stands out most in Oncology News Central’s annual Drug Report is not whether oncologists are adopting new therapies – they clearly are – but how deliberately they are doing so. Nearly 90% of clinicians reported prescribing at least one newly approved drug or indication in the past year; however, there is a parallel shift toward prescribing fewer new agents overall.
Open in Who Shared Issue with article?
See all 35 licensed articles (46 Total)